抗病毒治疗乙型肝炎肝硬化的过去、现在和将来

doi:10.3969/j.issn.1672-5069.2015.05.002

Abstract

Han Ying，Ding Huiguo. Antiviral therapy of patients with hepatitis B-induced liver cirrhosis:The past, present and future[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 453-456.

[1] Vallet-Pichard A，Mallet V，Costentin CE，et al. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther，2009，7（5）:527-535.
[2] Xu B，Xu GG，Guo Q，et al. Long term treatment of lamivudine in chronic hepatitis B patients with severe liver fibrosis-ten-year follow-up outcomes of NUCB 4006 trial. Chin J Infect Dis，2010，28（11）:656-661.
[3] Chang TT，Liaw YF，Wu SS，et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology，2010，52（3）:886-893.
[4] Fink SA，Jacobson IM. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol，2011，8（5）:285-295.
[5] Manolakopoulos S，Triantos C，Theodoropoulos J，et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol，2009，51（3）:468-474.
[6] Zhang QQ，An X，Liu YH，et al. Long-term nucleos（t）ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications:a meta-analysis. Virol J，2011，15（8）:72.
[7] Li CZ，Cheng LF，Li QS，et al. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol，2013，19:6849-6856.
[8] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol，2012，57（1）:167-185.
[9] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[10] Vallet-Pichard A，Mallet V，Costentin CE，et al. Treatment of HBV-related cirrhosis.Expert Rev Anti Infect Ther，2009，7（5）:527-535.
[11] Shin SK，Kim JH，Park H，et al. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis:2 years of entecavir treatment. J Gastroenterol Hepatol，2015，Jun 11. doi:10.1111/jgh.13020. [Epub ahead of print]. [12] Liaw YF，Sung JJ，Chow WC，et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med，2004，351（15）:1521-1531.
[13] Perrillo RP，Wright T，Rakela J，et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology，2001，33（2）:424-432.
[14] Schiff E，Lai CL，Hadziyannis S，et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results. Liver Transpl，2007，13（3）:349-360.
[15] Schiff ER，Lai CL，Hadziyannis S，et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients.Hepatology，2003，38（6）:1419-1427.
[16] Wong GL，Chan HL，Mak CW，et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology，2013，58（5）:1537-1547.
[17] Shim JH，Lee HC，Kim KM，et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis.J Hepatol，2010，52（2）:176-182.
[18] Chan HL，Chen YC，Gane EJ，et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat，2012，19（10）:732-743.
[19] Gane EJ，Deray G. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology，2014，146（1）:138-146.
[20] Koklü S，Tuna Y，Gülsen MT， et al. Long-term efficacy and safety of lamivudine，entecavir，and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol，2013，11（1）:88-94.
[21] Marcellin P，Buti M，Gane EJ，et al. Five years of treatment with tenofovir DF （TDF） for chronic hepatitis B（CHB） infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology，2011，54（Suppl）:1011A.
[22] Liaw YF，Gane E，Leung N，et al. GLOBE Study Group. 2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B.Gastroenterology，2009，136（2）:486-495.
[23] 任江波，王宇，李红艺，等．替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析．中华肝脏病杂志，2012；20（9）:641-643.
[24] Jung YK，Yeon JE，Choi JH，et al. Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver，2010，4（3）:389-393.
[25] Pol S，Lampertico P.First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings:from clinical trials to clinical practice. J Viral Hepat，2012，19（6）:377-386.

Antiviral therapy of patients with hepatitis B-induced liver cirrhosis:The past, present and future

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[9]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[10]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[13]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[14]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[15]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.